|Videos|August 24, 2022
Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM
Author(s)Sunandana Chandra, MD, MS
An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Trending on CURE
1
5 Years of Prostate Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
What Your Friend with Cancer REALLY Needs
3
Getting on My Ovarian Cancer Awareness Soap Box Again Because I Love My Daughter
4
FDA Grants Final Approval to OMCAZIO, a New Capsule Formulation of Cabozantinib
5